Concepedia

Publication | Open Access

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease

DOIFull Paper Access

27

Citations

10

References

2019

Year

Martín Cowie, André Lamy, Pierre Lévy, Stuart Mealing, A. Millier, Paul Mernagh, Olivier Cristeau, Kevin Bowrin, J Brière
Cardiovascular Research

Abstract

This Markov model suggests that rivaroxaban 2.5 mg bid plus ASA is a cost-effective alternative to ASA alone in patients with chronic CAD or PAD.

References

YearCitations

Page 1